Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated

MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE)  Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with CellBridge Incorporated (“CellBridge”) which grants it access to CellBridge’s 3D biomimetic support technology. This follows the Company’s recently announced license agreements with SyntArray, LLC and 48Hour Discovery and is the latest milestone in the Company’s strategy to bring together ground-breaking technologies to develop the next generation of patient derived (“PDx”) tumor models for The post Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated appeared first on Public Wire.
http://bit.ly/2GRbZuE